Has Sunita Nasta, MD received payments from drug or device companies?

Yes. Drug and device makers reported $82,121 in general payments to Sunita Nasta, MD across 94 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Sunita Nasta, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Sunita Nasta, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Sunita Nasta, MD

Hematology & Oncology · Philadelphia, PANPI 1336180108

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $71,784 of the $82,121 with a category attached, or 87.4%. 18 manufacturers reported payments, led by Merck at 40.0% of the total. 2025 is the largest year on record at $20,813, 3.3 times the $6,307 reported in 2019. Among hematology & oncology clinicians in PA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$82,121in general payments, 2019–2025

Across 94 payments — averaging $873.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Merck$33K
ADC Therapeutics America, Inc.$13K
Genmab U.S., Inc.$11K
AbbVie$8K
Incyte Corporation$7K
Acrotech Biopharma Inc.$6K
plus $5K from 12 others

$889,535in research payments, 2019–2025

Across 106 payments — averaging $8391.84 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Eli Lilly$362K
Genentech, Inc.$163K
Pharmacyclics LLC, An Abbvie Company$94K
Takeda Pharmaceuticals U.S.A., Inc.$83K
Taiho Oncology, Inc.$70K
Incyte Corporation$67K
plus $49K from 2 others

What the payments were for

Consulting fees$71,78487%
Speaking & faculty fees$1,8702%
Travel & lodging$5,2596%
Food & beverage$3,2084%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Merck	24	$32,850
ADC Therapeutics America, Inc.	10	$12,545
Genmab U.S., Inc.	20	$10,969
AbbVie	12	$7,538
Incyte Corporation	2	$7,075
Acrotech Biopharma Inc.	5	$6,161
Genentech USA, Inc.	6	$2,050
Epizyme, Inc.	1	$1,250
Deciphera Pharmaceuticals Inc.	1	$620
Pierre Fabre Pharmaceuticals, Inc.	2	$276
Bristol Myers Squibb	2	$209
Genentech, Inc.	2	$175
Novartis	2	$159
Eli Lilly	1	$125
Beone Medicines USA, Inc.	1	$35
AstraZeneca	1	$35
Adaptive Biotechnologies Corporation	1	$34
F. Hoffmann-la Roche AG	1	$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

EPKINLY$17,905
KEYTRUDA$17,632
Beleodaq$6,113
Lunsumio$1,828
Venclexta$1,700
TAZVERIK$1,250
POLIVY$386
Columvi$370
HEMANGEOL$211
Pomalyst$116

How this compares

$82,121 in reported general payments places this provider in the 90th percentile of 682 hematology & oncology providers in Pennsylvania.

See all hematology & oncology providers in Pennsylvania →

Medicare billing

Part B allowed, 2024

$136,555

Medicare patients

381

Services billed

1,595

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Acyclovir	12	$271
Prednisone	21	$94

Paid to pharmacies, not to this prescriber.

Other hematology & oncology in Philadelphia

Henry FungPhiladelphia$730K
Charu AggarwalPhiladelphia$541K
Corey LangerPhiladelphia$492K
Ankur ParikhPhiladelphia$329K
Catherine LaiPhiladelphia$281K
Stephen SchusterPhiladelphia$218K
Keith PratzPhiladelphia$173K
David PorterPhiladelphia$140K
Adam BinderPhiladelphia$136K
Marcela MausPhiladelphia$111K

See the full list for Pennsylvania →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →